IBRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
51.2M
+15.9%
44.2M
+15.5%
38.3M
+19.4%
32.1M
+21.3%
26.4M
Cost of Revenue
298.0K
+25.2%
238.0K
-37.7%
382.0K
+115.8%
177.0K
+30.1%
136.0K
Gross Profit
50.9M
+15.9%
44.0M
+16.0%
37.9M
+18.9%
31.9M
+21.3%
26.3M
Operating Expenses
112.6M
-1.0%
113.8M
+10.9%
102.6M
+17.2%
87.5M
-10.3%
97.6M
R&D
60.8M
-10.6%
68.0M
+6.5%
63.9M
+24.6%
51.2M
-7.2%
55.2M
SG&A
51.8M
+13.2%
45.8M
+18.2%
38.7M
+6.7%
36.3M
-14.3%
42.3M
Operating Income
-61697000
+11.6%
-69791000
-7.9%
-64683000
-16.3%
-55630000
+22.0%
-71285000
EBITDA
-57290000
+12.4%
-65411000
-7.6%
-60818000
-17.7%
-51679000
+23.3%
-67405000
Net Income
-230390000
+63.6%
-632797000
-921.3%
-61958000
+7.9%
-67274000
+27.3%
-92574000
EPS (Basic)
$-0.22
+64.5%
$-0.62
-933.3%
$-0.06
+14.3%
$-0.07
+30.0%
$-0.10
EPS (Diluted)
$-0.22
+64.5%
$-0.62
-933.3%
$-0.06
+14.3%
$-0.07
+30.0%
$-0.10
Shares (Diluted)
1.1B
+2.3%
1.0B
+3.6%
991.5M
+4.7%
946.6M
+6.6%
888.2M
ImmunityBio (IBRX) โ€” Financials